Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,849 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
Aogi K, Sakai H, Yoshizawa H, Masuda N, Katakami N, Yanagita Y, Inoue K, Kuranami M, Mizutani M, Masuda N. Aogi K, et al. Among authors: inoue k. Support Care Cancer. 2012 Jul;20(7):1507-14. doi: 10.1007/s00520-011-1239-0. Epub 2011 Aug 2. Support Care Cancer. 2012. PMID: 21808994 Clinical Trial.
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.
Suzuki Y, Saeki T, Aogi K, Toi M, Fujii H, Inoue K, Watanabe T, Fujiwara Y, Ito Y, Takatsuka Y, Iwata H, Arioka H, Tokuda Y. Suzuki Y, et al. Among authors: inoue k. Int J Clin Oncol. 2013 Aug;18(4):590-7. doi: 10.1007/s10147-012-0421-9. Epub 2012 May 15. Int J Clin Oncol. 2013. PMID: 22585426 Clinical Trial.
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, Yamamoto N, Inoue K, Ohono S, Kuroi K, Hamano T, Sukigara T, Fujiwara Y. Ando M, et al. Among authors: inoue k. Breast Cancer Res Treat. 2014 Jun;145(2):401-9. doi: 10.1007/s10549-014-2947-1. Epub 2014 Apr 12. Breast Cancer Res Treat. 2014. PMID: 24728578 Clinical Trial.
ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S, Inoue K, Takei H, Matsumoto H, Kurosumi M, Horiguchi J, Takeyoshi I, Oyama T. Kurozumi S, et al. Among authors: inoue k. BMC Cancer. 2015 Sep 7;15:622. doi: 10.1186/s12885-015-1641-y. BMC Cancer. 2015. PMID: 26345461 Free PMC article.
We're in this together: Patients', caregivers' and health care providers' illness perceptions about non-small-cell lung cancer (NSCLC).
Kaptein AA, Kobayashi K, Matsuda A, Kubota K, Nagai S, Momiyama M, Sugisaki M, Bos BC, Warning TD, Dik H, Klink Rv, Inoue K, Ramai R, Taube C, Kroep JR, Fischer MJ. Kaptein AA, et al. Among authors: inoue k. Lung Cancer. 2015 Dec;90(3):575-81. doi: 10.1016/j.lungcan.2015.10.017. Epub 2015 Oct 19. Lung Cancer. 2015. PMID: 26520188 Review.
Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
Kubota K, Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T. Kubota K, et al. Among authors: inoue k. Support Care Cancer. 2016 Sep;24(9):4025-33. doi: 10.1007/s00520-016-3203-5. Epub 2016 Apr 29. Support Care Cancer. 2016. PMID: 27129842 Free PMC article. Clinical Trial.
9,849 results